NANJING, China, August 20, 2026
Leads Biolabs announced that the full abstract for its Phase II study of LBL-024 (Opamtistomig) in combination with chemotherapy as a first-line treatment for non-small cell lung cancer (NSCLC) has been published by the World Conference on Lung Cancer (WCLC). The company said the study showed encouraging antitumor activity across both squamous and non-squamous NSCLC, while longer follow-up has indicated continued tumor shrinkage and a favorable progression-free survival trend. Updated results based on more than seven months of follow-up are scheduled for an oral presentation at WCLC on September 14, 2026.
LBL-024 Shows Encouraging Response in NSCLC
The published abstract evaluated 60 efficacy-evaluable patients with locally advanced or metastatic NSCLC who received LBL-024 plus chemotherapy in the first-line setting. The combination produced an objective response rate (ORR) of 65.0% and a disease control rate (DCR) of 95.0% in the overall population. Activity was observed across the two major NSCLC histological subgroups, with the squamous population recording an ORR of 77.4% and DCR of 96.8%, while the non-squamous population achieved an ORR of 51.7% and DCR of 93.1%. The safety profile was reported as manageable, with no new safety signals identified. These findings are particularly relevant to first-line NSCLC, where improving the depth and durability of tumor responses remains an important area of clinical development.
Extended Follow-Up to Provide Durability Insights
The currently published data were based on a median follow-up of 3.6 months, meaning the dataset remains relatively early for assessing long-term treatment durability. Leads Biolabs said observations from longer treatment and follow-up have shown continued tumor shrinkage in some patients, accompanied by an upward trend in ORR and a favorable trend in progression-free survival (PFS). The upcoming WCLC presentation is expected to provide a more mature assessment of the program, including the updated ORR, six-month PFS rate and subgroup analyses according to PD-L1 expression in both squamous and non-squamous NSCLC. The company is using these data to further evaluate whether LBL-024 can deliver increasingly deep and durable responses with continued treatment.
Advertisement
PD-L1/4-1BB Bispecific Approach Supports Broader Development
LBL-024 is a PD-L1/4-1BB bispecific antibody designed to combine two complementary immune mechanisms in a single therapeutic approach. Leads Biolabs describes the strategy as intended to both release the immune-system “brake” through PD-L1 targeting and activate the immune response through 4-1BB stimulation. The company is positioning this mechanism as a potential “IO 2.0” approach for cancer treatment. LBL-024 is currently being evaluated in 11 clinical studies across multiple tumor types, with clinical signals reported across its first seven indications. The company said the latest NSCLC findings, together with the planned extended follow-up presentation at WCLC, will help further define the candidate’s potential across different patient populations. The September presentation will therefore be an important next data point for assessing the durability, depth and consistency of response associated with LBL-024 in first-line NSCLC.
Source: Leads Biolabs press relese
